Scarica l'app Stockscreener
4.12
1.23%
0.05
Dopo l'orario di chiusura:
4.11
-0.010
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.07
Aprire:
$4.18
Volume 24 ore:
18.81M
Relative Volume:
0.96
Capitalizzazione di mercato:
$2.21B
Reddito:
$66.41M
Utile/perdita netta:
$-559.78M
Rapporto P/E:
-3.4271
EPS:
-1.2022
Flusso di cassa netto:
$-328.09M
1 W Prestazione:
+10.16%
1M Prestazione:
+21.89%
6M Prestazione:
+32.48%
1 anno Prestazione:
-25.36%
Intervallo 1D:
$4.01
$4.27
Intervallo di 1 settimana:
$3.665
$4.29
Portata 52W:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.12 | 2.01B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX Stock Rises As Tempus AI Deal Resets Growth Story - StocksToTrade
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - TradingView
Recursion Pharmaceuticals (RXRX) Short Interest & Short Float | Updated Sep 2026 $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Shares Just Moved, So What Is Driving Attention Now? - Simply Wall Street
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know - Yahoo Finance
RXRX Extends Tempus Deal As Stock Climbs On Predictable Cash - timothysykes.com
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: High Potential Upside in the Biotech Sector - DirectorsTalk Interviews
RXRX Stock Grinds Higher As Insider Filings Stack Up - timothysykes.com
A data partnership shifts from potential $84 million in two-year fees to $42 million in committed payments over three - Stock Titan
Recursion Pharmaceuticals (NASDAQ: RXRX) Lowers Tempus Annual Fees to $14 Million - Kalkine Media
Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model - marketscreener.com
Recursion, Tempus Expand AI and RNA Collaboration Agreements - TipRanks
Recursion Resets Tempus Data Pact and Licenses TxFM RNA Model in $12M Deal - TradingView
Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026SEC Filing - TradingView
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound? - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
RXRX Stock Holds Support As Insider Form 4s Hit Tape - StocksToTrade
RXRX Stock Steadies As Insider Activity Draws Trader Focus - timothysykes.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Options ChainYahoo Finance - Yahoo! Finance Canada
RXRX Stock Holds Steady As Insider Form 4 Filings Stack Up - timothysykes.com
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Recursion Pharmaceuticals (RXRX): Can Its AI Platform Translate Into Clinical Wins? - RTTNews
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - finance.yahoo.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Conference Updates and Partnerships - Moomoo
Recursion at Morgan Stanley conference: AI platform moves into clinic - Investing.com
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
Recursion (NASDAQ: RXRX) officer moves to sell stock - Stock Titan
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):